Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.49 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788165 | 0.81 | HSD17B1 (0.52) | HSD17B1HSD17B2TRPV3CTSSCTSK | |
| SCHEMBL16385400 | 0.81 | CTSS (0.55) | TRPV3CTSSCTSKAR | |
| SCHEMBL16385294 | 0.80 | HSD17B1 (0.51) | HSD17B1HSD17B2ARIRAK4ESR1 | |
| SCHEMBL21508309 | 0.78 | AAK1 (0.50) | HSD17B1HSD17B2CTSSCTSKESR1 | |
| SCHEMBL12468546 | 0.74 | HSD17B1 (0.45) | HSD17B1HSD17B2 | |
| SCHEMBL20878875 | 0.71 | MAP4K4 (0.47) | TRPV3 | |
| SCHEMBL13831046 | 0.71 | CYP1A2 (0.46) | HSD17B1HSD17B2ARIRAK4ESR1 | |
| SCHEMBL29485676 | 0.71 | HSD17B1 (0.65) | HSD17B1HSD17B2ARESR1ESR2 | |
| SCHEMBL1938893 | 0.71 | HSD17B1 (0.65) | HSD17B1HSD17B2ARESR1ESR2 | |
| SCHEMBL13273049 | 0.71 | MEN1 (0.43) | HSD17B1HSD17B2TRPV3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| WO-2015005499-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SOD1, UQCRB, MT-CO1 | HSD17B1 1419/4885HSD17B2 2000/4885TRPV3 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.